Muscular Dystrophy - Pipeline Review, H1 2013
Global Markets Direct’s, 'Muscular Dystrophy - Pipeline Review, H1 201...
comparative Analysis
early Clinical Stage Products
comparative Analysis
discovery And Pre-clinical Stage Products
comparat...
r&d Progress
raav1.tmck.human-alpha-sarcoglycan - Drug Profile
product Description
mechanism Of Action
r&d Progress
gamma-...
mechanism Of Action
r&d Progress
cyclophilin Inhibitory Compounds - Drug Profile
product Description
mechanism Of Action
r...
product Description
mechanism Of Action
r&d Progress
val-1205 - Drug Profile
product Description
mechanism Of Action
r&d P...
M/s Sheela,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-99...
Upcoming SlideShare
Loading in …5
×

Muscular Dystrophy Pipeline Review, H1 2013

115
-1

Published on

Muscular Dystrophy - Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Published in: Health & Medicine, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
115
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
3
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Muscular Dystrophy Pipeline Review, H1 2013

  1. 1. Muscular Dystrophy - Pipeline Review, H1 2013 Global Markets Direct’s, 'Muscular Dystrophy - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Muscular Dystrophy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Muscular Dystrophy. Muscular Dystrophy - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope A snapshot of the global therapeutic scenario for Muscular Dystrophy. A review of the Muscular Dystrophy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. Coverage of products based on various stages of development ranging from discovery till registration stages. A feature on pipeline projects on the basis of monotherapy and combined therapeutics. Coverage of the Muscular Dystrophy pipeline on the basis of route of administration and molecule type. Key discontinued pipeline projects. Latest news and deals relating to the products. Reasons to buy Identify and understand important and diverse types of therapeutics under development for Muscular Dystrophy. Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. Devise corrective measures for pipeline projects by understanding Muscular Dystrophy pipeline depth and focus of Indication therapeutics. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. table Of Content introduction global Markets Direct Report Coverage muscular Dystrophy Overview therapeutics Development an Overview Of Pipeline Products For Muscular Dystrophy muscular Dystrophy Therapeutics Under Development By Companies muscular Dystrophy Therapeutics Under Investigation By Universities/institutes mid Clinical Stage Products Muscular Dystrophy - Pipeline Review, H1 2013
  2. 2. comparative Analysis early Clinical Stage Products comparative Analysis discovery And Pre-clinical Stage Products comparative Analysis muscular Dystrophy Therapeutics – Products Under Development By Companies muscular Dystrophy Therapeutics – Products Under Investigation By Universities/institutes companies Involved In Muscular Dystrophy Therapeutics Development genzyme Corporation mdrna, Inc. pfizer Inc. benitec Ltd. calzada Limited nutra Pharma Corporation santhera Pharmaceuticals Holding Ag scynexis, Inc. fate Therapeutics, Inc. sanbio, Inc. prosensa Therapeutics B.v. muscular Dystrophy – Therapeutics Assessment assessment By Monotherapy Products assessment By Route Of Administration assessment By Molecule Type drug Profiles aod-9604 - Drug Profile product Description mechanism Of Action r&d Progress omigapil - Drug Profile product Description mechanism Of Action r&d Progress sb-308 - Drug Profile product Description mechanism Of Action r&d Progress ligand-1 - Drug Profile product Description mechanism Of Action r&d Progress pro-135 - Drug Profile product Description mechanism Of Action Muscular Dystrophy - Pipeline Review, H1 2013
  3. 3. r&d Progress raav1.tmck.human-alpha-sarcoglycan - Drug Profile product Description mechanism Of Action r&d Progress gamma-sarcoglycan Gene Therapy - Drug Profile product Description mechanism Of Action r&d Progress gamma-sarcoglycan Gene Therapy - Drug Profile product Description mechanism Of Action r&d Progress ft-301 - Drug Profile product Description mechanism Of Action r&d Progress prt-01 - Drug Profile product Description mechanism Of Action r&d Progress prt-300 - Drug Profile product Description mechanism Of Action r&d Progress wnt7a--based Protein Thearpeutics - Drug Profile product Description mechanism Of Action r&d Progress pf-06252616 - Drug Profile product Description mechanism Of Action r&d Progress ddrnai Program For Oculopharyngeal Muscular Dystrophy - Drug Profile product Description mechanism Of Action r&d Progress aav5 Gene Therapy - Drug Profile product Description mechanism Of Action r&d Progress sirolimus - Drug Profile product Description Muscular Dystrophy - Pipeline Review, H1 2013
  4. 4. mechanism Of Action r&d Progress cyclophilin Inhibitory Compounds - Drug Profile product Description mechanism Of Action r&d Progress rnase H-active Antisense Oligos - Drug Profile product Description mechanism Of Action r&d Progress vlt-001 - Drug Profile product Description mechanism Of Action r&d Progress vlt-002 - Drug Profile product Description mechanism Of Action r&d Progress drug For Myotonic Dystrophy - Drug Profile product Description mechanism Of Action r&d Progress drug For Myotonic Dystrophy - Drug Profile product Description mechanism Of Action r&d Progress val-0411 - Drug Profile product Description mechanism Of Action r&d Progress muscular Dystrophy Program - Drug Profile product Description mechanism Of Action r&d Progress gsmtx-4 - Drug Profile product Description mechanism Of Action r&d Progress srt-149 - Drug Profile product Description mechanism Of Action r&d Progress srt-152 - Drug Profile Muscular Dystrophy - Pipeline Review, H1 2013
  5. 5. product Description mechanism Of Action r&d Progress val-1205 - Drug Profile product Description mechanism Of Action r&d Progress muscular Dystrophy Therapeutics – Drug Profile Updates muscular Dystrophy Therapeutics – Discontinued Products muscular Dystrophy Therapeutics - Dormant Products muscular Dystrophy – Product Development Milestones featured News & Press Releases dec 03, 2012: Benitec Biopharma’s Muscular Dystrophy Program Demonstrates Significant Gene Silencing apr 11, 2012: Santhera Pharma Joins Eu-funded Endostem Consortium In Preparation For Clinical Study With Omigapil In Congenital Muscular Dystrophies dec 14, 2011: Calzada Announces New Applications For Aod9604 sep 23, 2011: Prothelia's Laminin-111 Receives Orphan Drug Designation For Treatment Of Congenital Muscular Dystrophy feb 08, 2011: Santhera Obtains Us And Canadian Patents For Use Of Omigapil For Treatment Of Congenital Muscular Dystrophy dec 07, 2010: Santhera Wins European Patent For Use Of Omigapil In Treatment Of Congenital Muscular Dystrophy oct 31, 2006: Avanir Receives Approvable Letter From Fda For Zenvia. appendix methodology coverage secondary Research primary Research expert Panel Validation contact Us disclaimer ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price. Contact: Muscular Dystrophy - Pipeline Review, H1 2013
  6. 6. M/s Sheela, 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-997-4948 Email: sales@researchmoz.us Website: http://www.researchmoz.us/ Muscular Dystrophy - Pipeline Review, H1 2013

×